BIOHAVEN PHARMACEUTICAL
Biohaven is a clinical-stage biopharmaceutical company. It has a portfolio of late-stage product candidates targeting neurological diseases, including rare disorders. The company product candidates are based on multiple mechanisms-calcitonin gene-related peptide receptor antagonists, glutamate modulators and myeloperoxidase inhibitor. Its pipeline products include BHV3000-301, BHV3000-302, BHV3000-303, and others.
BIOHAVEN PHARMACEUTICAL
Industry:
Biotechnology Health Care Health Diagnostics Neuroscience Pharmaceutical
Founded:
2013-01-01
Address:
New Haven, Connecticut, United States
Country:
United States
Website Url:
http://www.biohavenpharma.com
Total Employee:
1001+
Status:
Active
Total Funding:
443.7 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Tag Manager Font Awesome Mobile Non Scaleable Content IPv6 Google Maps ReCAPTCHA Cloudflare JS CDN JS
Similar Organizations
Aura Biosciences
Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor targeted pseudovirions.
Idera Pharmaceuticals
Idera Pharmaceuticals is engaged in the discovery and development of novel synthetic DNA and RNA-based drug candidates.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2021-01-07 | Kleo | Kleo acquired by Biohaven Pharmaceutical | 20 M USD |
Investors List
Soros Fund Management
Soros Fund Management investment in Post-IPO Equity - Biohaven Pharmaceutical
Venrock
Venrock investment in Venture Round - Biohaven Pharmaceutical
RA Capital Management
RA Capital Management investment in Venture Round - Biohaven Pharmaceutical
Rock Springs Capital
Rock Springs Capital investment in Venture Round - Biohaven Pharmaceutical
OUP (Osage University Partners)
OUP (Osage University Partners) investment in Venture Round - Biohaven Pharmaceutical
Aisling Capital
Aisling Capital investment in Venture Round - Biohaven Pharmaceutical
Greg Bailey
Greg Bailey investment in Venture Round - Biohaven Pharmaceutical
Knoll Capital Management
Knoll Capital Management investment in Venture Round - Biohaven Pharmaceutical
Connecticut Innovations
Connecticut Innovations investment in Venture Round - Biohaven Pharmaceutical
Litmore Capital
Litmore Capital investment in Venture Round - Biohaven Pharmaceutical
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2021-03-01 | Artizan Biosciences | Biohaven Pharmaceutical investment in Series A - Artizan Biosciences | 18.88 M USD |
| 2018-11-14 | Kleo | Biohaven Pharmaceutical investment in Series B - Kleo | 21 M USD |
| 2016-09-01 | Kleo | Biohaven Pharmaceutical investment in Series A - Kleo | N/A |
Official Site Inspections
http://www.biohavenpharma.com Semrush global rank: 1.11 M Semrush visits lastest month: 29.03 K
- Host name: ec2-3-130-137-99.us-east-2.compute.amazonaws.com
- IP address: 3.130.137.99
- Location: Columbus United States
- Latitude: 39.9653
- Longitude: -83.0235
- Metro Code: 535
- Timezone: America/New_York
- Postal: 43215
More informations about "Biohaven Pharmaceutical"
Commitment to Patients, Winning with Science | Biohaven
CHALLENGING THE STATUS QUO. At Biohaven, we are guided by science and inspired to change the lives of people with unmet medical needs. Harnessing our non-hierarchical, …See details»
Biohaven Pharmaceutical - Crunchbase Company Profile & Funding
Biohaven is a clinical-stage biopharmaceutical company. It has a portfolio of late-stage product candidates targeting neurological diseases, including rare disorders.See details»
Overview - Biohaven, Ltd.
Nov 12, 2024 The Investor Relations website contains information about Biohaven, Ltd.'s business for stockholders, potential investors, and financial analysts.See details»
Our People | Biohaven
Prior to Biohaven Taina, worked at Alexion Pharmaceuticals as an Executive Assistant supporting the CFO and various members of the executive team before transitioning to the Sourcing …See details»
Latest Clinical Trials | Biohaven
Major Depressive Disorder A Study to Evaluate the Efficacy and Safety of BHV-7000 Monotherapy in Major Depressive Disorder. Drug: BHV-7000 Age: 18-75See details»
Biohaven - LinkedIn
Biohaven is a uniquely different pharmaceutical company. We are an agile and resilient team of highly skilled professionals who eagerly challenge the status quo to advance novel, life …See details»
Biohaven Pharmaceutical - Craft
Biohaven is engaged in the identification and development of clinical stage compounds targeting the glutamatergic system. Biohaven obtained licenses from Yale University School of Medicine …See details»
Pfizer Completes Acquisition of Biohaven Pharmaceuticals
Oct 3, 2022 Acquisition adds breakthrough calcitonin gene-related peptide portfolio, including NURTEC® ODT, to address needs of millions of migraine patients worldwide Pfizer Inc. …See details»
Pfizer to Acquire Biohaven Pharmaceuticals - s28.q4cdn.com
[email protected] +1 (201) 248-0741 . Mike Beyer, Sam Brown Inc. [email protected] +1 (312) 961-2502 . Pfizer to Acquire Biohaven Pharmaceuticals . …See details»
Royalty Pharma and Biohaven Announce Funding Agreement …
Aug 7, 2020 For more information, visit www.biohavenpharma.com. Royalty Pharma Investor Relations and Communications +1 (212) 883-2295. [email protected]. Biohaven Contact. …See details»
Biohaven Highlights Progress Across Innovative Portfolio and …
Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing …See details»
Pfizer to Acquire Biohaven Pharmaceuticals
May 10, 2022 Pfizer to commercialize NURTEC® ODT (rimegepant), an innovative compound for the prevention and acute treatment of migraine, a condition with high unmet need Expands …See details»
Biohaven and Pfizer Enter Strategic Collaboration for the ...
Nov 9, 2021 To access the call, please dial 877-407-9120 (domestic) or 412-902-1009 (international). The conference call webcast and accompanying slide presentation can be …See details»
Biohaven and Pfizer Enter Strategic Collaboration for the ...
Nov 9, 2021 The World Health Organization classifies migraine as one of the 10 most disabling medical illnesses. Migraine is characterized by debilitating headache attacks lasting four to 72 …See details»
Pfizer Completes Acquisition of Biohaven Pharmaceuticals
Oct 3, 2022 Pfizer Inc. (NYSE: PFE) announced today the completion of its acquisition of Biohaven Pharmaceutical Holding Company Ltd., the maker of NURTEC® ODT (rSee details»
Biohaven Completes Enrollment in Pivotal Phase 3 Study of …
Sep 14, 2023 Lindsey Lair, MD, Biohaven Vice President, Clinical Development Lead for the SMA program stated, "We are thrilled to complete enrollment in this pivotal trial for SMA as it …See details»
Biohaven and Pfizer Enter Strategic Collaboration for the ...
Nov 9, 2021 More information about Biohaven is available at www.biohavenpharma.com. Biohaven Forward-looking Statement This news release includes forward-looking statements …See details»
Pfizer to Acquire Biohaven Pharmaceuticals - Business Wire
May 10, 2022 The World Health Organization classifies migraine as one of the 10 most disabling medical illnesses. ... Jen Porcelli, VP, Investor Relations …See details»
Biohaven and Pfizer Complete Collaboration Transaction for ...
Jan 5, 2022 The World Health Organization classifies migraine as one of the 10 most disabling medical illnesses. Migraine is characterized by debilitating headache attacks lasting four to 72 …See details»